To evaluate the expression and prognostic value of RARRES1 at protein level in renal cell carcinoma (RCC).
Expression profile of RARRES1 was analyzed in 903 documented RCC followed by clinicopathological correlations and survival analysis.
RARRES1 expression was seen in 72.5% of RCC. A stronger RARRES1 expression was seen in high grade compared with low grade RCC (p < 0.001). Logrank tests revealed shorter overall survival in RARRES1 positive RCC (p = 0.006) and in pT1/2 tumors with RARRES1 expression (p = 0.002).
The variable expression profile in low and high grade RCC may reflect and confirm the differences of previous gene expression analysis. There was a significant prognostic value of RARRES1 expression in patients with RCC, especially in pT1/2 tumors.
Biomarkers in medicine. 2016 Jun 24 [Epub ahead of print]
Annette Zimpfer, Friedericke Dammert, Aenne Glass, Heike Zettl, Ergin Kilic, Matthias Maruschke, Oliver W Hakenberg, Andreas Erbersdobler
Institute of Pathology, University Medicine Rostock, Strempelstr. 14, 18055 Rostock, Germany., Institute of Pathology, University Medicine Rostock, Strempelstr. 14, 18055 Rostock, Germany., Institute of Biostatistics, University of Rostock, Ernst-Heydemann-Str. 8, 18057 Rostock, Germany., Clinical Cancer Registry, University Medicine Rostock, Südring 75, 18059 Rostock, Germany., Institute of Pathology, Charité University Medicine, Chariteplatz 1, 10177 Berlin Germany., Clinic of Urology, HELIOS Hanseklinikum Stralsund, Große Parower Straße 47-53, 18435 Stralsund, Germany., Clinic of Urology, University Medicine Rostock, Ernst-Heydemann-Str. 8, 18057 Rostock, Germany., Institute of Pathology, University Medicine Rostock, Strempelstr. 14, 18055 Rostock, Germany.